Evidence map›Paper›PMID 27164657›Full record

ArticleNeurology2016

Multimorbidity and neuroimaging biomarkers among cognitively normal persons.

Maria Vassilaki, Jeremiah A Aakre, Michelle M Mielke, Yonas E Geda, Walter K Kremers, Rabe E Alhurani, Mary M Machulda, David S Knopman, Ronald C Petersen, Val J Lowe and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Multimorbidity in dementia: Current perspectives and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cardiometabolic multimorbidity, peripheral biomarkers, and dementia in rural older adults: The MIND-China study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  13. Blood biomarkers of Alzheimer's disease in the community: Variation by chronic diseases and inflammatory status.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Disease Burden Affects Aging Brain Function.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Maria VassilakiFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN. roberts.rosebud@mayo.edu Vassilaki.Maria@mayo.edu.
Jeremiah A AakreFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Michelle M MielkeFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Yonas E GedaFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Walter K KremersFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Rabe E AlhuraniFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Mary M MachuldaFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
David S KnopmanFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Ronald C PetersenFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Val J LoweFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Clifford R JackFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN.
Rosebud O RobertsFrom the Departments of Health Sciences Research (M.V., J.A.A., M.M. Mielke, Y.E.G., W.K.K., R.C.P., R.O.R.) and Neurology (M.M. Mielke, Y.E.G., R.E.A., D.S.K., R.C.P., R.O.R.), Mayo Clinic, Rochester, MN; Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ; Mayo Clinic Graduate School of Medicine (R.E.A.), Rochester, MN; and Departments of Psychiatry and Psychology (M.M. Machulda) and Radiology (V.J.L., C.R.J.), Mayo Clinic, Rochester, MN. roberts.rosebud@mayo.edu Vassilaki.Maria@mayo.edu.
Mayo Clinic in Arizona · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Aerobic Exercise in Alzheimer's Disease: Cognition and Hippocampal Volume EffectsR01AG043392 · NIA · UNIVERSITY OF MINNESOTA · PI YU, FANG · 2013 to 2018
$3.2M
Stroke and Cognitive Impairment in Aging Chronic Kidney Disease PatientsR01AG037551 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MURRAY, ANNE M · 2011 to 2015
$2.7M
Vascular /Inflammatory Predictors of MCI Risk /ProgressiK01AG028573 · NIA · MAYO CLINIC ROCHESTER · PI ROBERTS, ROSEBUD O · 2006 to 2008
$351k
NCATS NIH HHS UL1 TR000135NIA NIH HHS K01 AG028573NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG037551NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG043392NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

objectiveTo assess the cross-sectional association between multimorbidity and imaging biomarkers of brain pathology in the population-based Mayo Clinic Study of Aging (MCSA).

methodsThe study consisted of 1,449 MCSA participants who were cognitively normal at the time of MRI. A subset of the participants also had (11)C-Pittsburgh compound B (n = 689) and (18)fluorodeoxyglucose (n = 688) PET scans available. Information on multimorbidity (defined as ≥2 chronic conditions) in the 5 years prior to the first imaging study was captured from the medical record using ICD-9 codes for chronic conditions and the Rochester Epidemiology Project medical records linkage system. The cross-sectional association of multimorbidity and imaging biomarkers was examined using logistic and linear regression models.

resultsAmong 1,449 cognitively normal participants (mean age 79 years; 50.9% men), 85.4% had multimorbidity (≥2 chronic conditions). Multimorbidity and severe multimorbidity (≥4 chronic conditions) were associated with abnormal Alzheimer disease (AD) signature meta-region of interest (meta-ROI) (18)F-FDG hypometabolism (odds ratio [OR] 2.03; 95% confidence interval [CI] 1.10-3.77 and OR 2.22; 95% CI 1.18-4.16, respectively), and with abnormal AD signature MRI cortical thickness (OR 1.53; 95% CI 1.09-2.16 and OR 1.76; 95% CI 1.24-2.51, respectively), but was not associated with amyloid accumulation.

conclusionsMultimorbidity was associated with brain pathology through mechanisms independent of amyloid deposition and such neuronal injury and pathology was present before any symptomatic evidence of cognitive impairment. Longitudinal follow-up will provide insights into potential causal associations of multimorbidity with changes in brain pathology.

Indexed as

CognitionComorbidityMagnetic Resonance ImagingNeuroimagingPositron-Emission TomographyAgedAged, 80 and overAgingAmyloidAniline CompoundsBrainCross-Sectional StudiesFemaleFluorodeoxyglucose F18HumansLinear Models2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloidAniline CompoundsFluorodeoxyglucose F18RadiopharmaceuticalsThiazoles

Identifiers

PMID27164657
PMCPMC4891208
OpenAlexW2341900421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.